ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease

Pharmacogenomics J. 2010 Jun;10(3):161-4. doi: 10.1038/tpj.2009.58. Epub 2009 Dec 8.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial

MeSH terms

  • Aged, 80 and over
  • Alleles
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / genetics*
  • Apolipoproteins E / genetics*
  • Biomarkers / analysis*
  • Clinical Trials, Phase II as Topic / methods
  • Cognition / physiology
  • Disease Progression
  • Female
  • Humans
  • Male

Substances

  • Apolipoproteins E
  • Biomarkers